PerkinElmer's subsidiary Wallac will now distribute the Amplidiag product line in Israel and in a number of countries in Africa.
Applied Biocode intends to have panel for identifying 18 gastrointestinal pathogens on the clinical market by the end of the year.
The BD Max Enteric Panel is the latest in the BD Max suite of assays that aid in the diagnosis of infectious gastroenteritis.
The impact study included time-motion analysis of all steps for the EBP compared to stool culture.
The firm's approach to panels is more focused than the competition, according to a BD executive.
Xpert Norovirus is a qualitative in vitro diagnostic test for the identification and differentiation of norovirus genogroup I and genogroup II.
The company makes tests with rapid time-to-results intended for high-volume hospital and pathology labs using its proprietary diagnostic technology, 3Base.
NEW YORK (GenomeWeb) – Luminex said after the close of the market on Monday that the US Food and Drug Administration has cleared three additional targets for its xTAG Gastrointestinal Pathogen Panel.
NEW YORK (GenomeWeb) — Finnish molecular diagnostics firm Mobidiag said today that its Amplidiag Bacterial GE assay has received CE IVD marking and is now commercially available in Europe.
NEW YORK (GenomeWeb) – Becton Dickinson today said that the US Food and Drug Administration has cleared for marketing the firm's BD Max Enteric Bacterial Panel for detecting the common causes of bacterial gastroenteritis.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.